Phosphatidylserine-blocking nanoparticles inhibit thrombosis without increased bleeding in mice
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2024.10.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Jeremy G T Wurtzel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cardeza Foundation for Hematologic Research, Department of Medicine, Division of Hematology, Sidney Kimmel Medical College, Thomas Jefferson Universi…. Hauptthemen laut MEDLINE: Phosphatidylserines, Thrombosis, Hemorrhage, Nanoparticles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institutes of Health, National Heart Lung and Blood Institute.
Abstract (Originalsprache)
BACKGROUND: Phosphatidylserine (PS) is a procoagulant phospholipid enriched on surfaces of activated vascular cells including platelets, endothelium, monocytes, and microvesicles. As a molecular driver of thrombosis accessible to drug blockade, PS is an attractive pharmacologic target for modulating thrombogenesis, with potentially reduced bleeding risk compared to anticoagulant and antiplatelet therapies. OBJECTIVES: Test antithrombotic capabilities of a liposomal formulation, Zn-dipicolylamine cyanine-3[22,22]/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (molar ratio, 3:97), designated as DPAL, which we previously described binds selectively to PS-enriched cell surfaces, compared with effects on bleeding, in mouse models. METHODS: PS-dependent DPAL binding to human and murine platelets was tested in vitro. Thrombosis and bleeding after DPAL intravenous administration were tested in C57Bl/6J mice following FeCl3 carotid arterial injury and tail tip amputation, respectively. Incorporation in hemostatic clots was investigated in the cremaster muscle laser injury model. Toxicity was tested by direct exposure to human endothelial cell cultures. RESULTS: DPAL bound agonist-stimulated, PS-positive human and murine platelets, blocked by Annexin V or Ano6 deletion, which ablate PS exposure. DPAL prolonged prothrombin time, but did not prevent thrombin-induced fibrinogen receptor activation or aggregation, nor alter blood cell counts including platelets. Following arteriolar laser injury, DPAL bound wound surfaces and edges without destabilizing plugs. DPAL dose-dependently blocked FeCl3-induced arterial thrombosis but did not substantially increase bleeding, or induce endothelial cell death. CONCLUSION: DPAL reduces thrombogenesis with minimal effects on bleeding in mouse models via selective binding to PS. DPAL may support novel approaches to modulate pathogenic thrombin generation with improved safety profiles in multiple contexts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardeza Foundation for Hematologic Research, Department of Medicine, Division of Hematology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Molecular Targeting Technologies Inc, West Chester, Pennsylvania, USA.
- Department of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
- Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
- Sol Sherry Thrombosis Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
- Sol Sherry Thrombosis Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA; Department of Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylva…
Förderung
- NHLBI NIH HHS
- National Institutes of Health
- National Heart Lung and Blood Institute
- W W Smith Charitable Trust
- American Heart Association Inc
Zitieren
APA
Wurtzel, J. G. T., Gray, B. D., Pak, K. Y., Zhao, X., Ma, P., McKenzie, S. E., Tanujaya, M., Rizzo, V., Del Carpio-Cano, F., Rao, A. K., Lee-Gau Chong, P., & Goldfinger, L. E. (2025). Phosphatidylserine-blocking nanoparticles inhibit thrombosis without increased bleeding in mice. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.10.007
Vancouver
Wurtzel JGT, Gray BD, Pak KY, Zhao X, Ma P, McKenzie SE, et al. Phosphatidylserine-blocking nanoparticles inhibit thrombosis without increased bleeding in mice. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2024.10.007
BibTeX
@article{Wurtzel2025,
author = {Wurtzel, Jeremy G T and Gray, Brian D and Pak, Koon Y and Zhao, Xuefei and Ma, Peisong and McKenzie, Steven E and Tanujaya, Michelle and Rizzo, Victor and Del Carpio-Cano, Fabiola and Rao, A Koneti and Lee-Gau Chong, Parkson and Goldfinger, Lawrence E},
title = {Phosphatidylserine-blocking nanoparticles inhibit thrombosis without increased bleeding in mice},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2024.10.007}
}
EUVIMED